News archive
News Archive Navigation
icon
News Archive Navigation Language
Showing 672 results
May 2010
-
Media ReleaseUS Affiliate of Novartis Strongly Disputes Claims of Past Discrimination in the US- The Novartis US affiliate, Novartis Pharmaceuticals Corporation (NPC), is committed to active and progressive policies and programs supporting the advancement of women in the sales force- NPC…
-
Media ReleaseUS Affiliate of Novartis Strongly Disputes Claims of Past Discrimination in the US
October 2009
-
Media ReleaseNovartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court- Alabama Supreme Court directs entry of final judgment in favor of NPC- Alabama Supreme Court ruling confirms State of Alabama's claims unfounded- NPC pleased by ruling, as the company reported true…
-
Media ReleaseNovartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
July 2009
-
Media ReleaseFDA Approves Tekturna HCT® as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent- Tekturna HCT combines the only approved direct renin inhibitor, Tekturna®, with widely used diuretic, hydrochlorothiazide, in a single pill- Data show combination of Tekturna and…
-
Media ReleaseFDA Approves Tekturna HCT® as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent
June 2009
-
Media ReleaseVideo: New Biological Therapy Ilaris® Approved in US to Treat Children and Adults with CAPS, a Serious Life-Long Auto-Inflammatory Disease- Phase III data show rapid and sustained remission in more than 90% of Ilaris-treated patients with cryopyrin-associated periodic syndrome (CAPS) - Ilaris is the first approved treatment for…
-
Media ReleaseVideo: New Biological Therapy Ilaris® Approved in US to Treat Children and Adults with CAPS, a Serious Life-Long Auto-Inflammatory Disease
April 2009
-
Media ReleaseVideo: FDA approves Exforge HCT® - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill- Exforge HCT combines a proven calcium channel blocker, angiotensin receptor blocker and diuretic (amlodipine, valsartan, hydrochlorothiazide) in one pill - In a clinical trial, Exforge HCT…
-
Media ReleaseVideo: FDA approves Exforge HCT® - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill
Pagination
- ‹ Previous page
- 1
- …
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- › Next page